Embecta (NASDAQ:EMBC - Get Free Report) will likely be releasing its earnings data before the market opens on Friday, February 14th. Analysts expect Embecta to post earnings of $0.45 per share for the quarter. Embecta has set its FY 2025 guidance at 2.700-2.900 EPS.Persons interested in listening to the company's earnings conference call can do so using this link.
Embecta (NASDAQ:EMBC - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.65 EPS for the quarter, topping the consensus estimate of $0.45 by $0.20. Embecta had a net margin of 5.25% and a negative return on equity of 19.22%. On average, analysts expect Embecta to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.
Embecta Stock Performance
EMBC stock traded up $0.08 during midday trading on Monday, reaching $17.50. 672,469 shares of the company's stock traded hands, compared to its average volume of 395,091. The firm has a market capitalization of $1.02 billion, a PE ratio of 17.50, a price-to-earnings-growth ratio of 0.95 and a beta of 1.20. The company has a 50-day moving average price of $19.58 and a two-hundred day moving average price of $16.55. Embecta has a 52 week low of $9.93 and a 52 week high of $21.48.
Embecta Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 14th. Investors of record on Friday, February 28th will be paid a dividend of $0.15 per share. The ex-dividend date of this dividend is Friday, February 28th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 3.43%. Embecta's payout ratio is 60.00%.
Analysts Set New Price Targets
A number of research analysts have weighed in on EMBC shares. BTIG Research raised Embecta from a "neutral" rating to a "buy" rating and set a $26.00 target price for the company in a report on Wednesday, November 27th. Morgan Stanley raised shares of Embecta from an "underweight" rating to an "equal weight" rating and boosted their price objective for the company from $13.00 to $20.00 in a research note on Monday, December 2nd.
View Our Latest Analysis on Embecta
Embecta Company Profile
(
Get Free Report)
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.
Recommended Stories

Before you consider Embecta, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Embecta wasn't on the list.
While Embecta currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.